BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Asandeutertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Asandeutertinib\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06672068-2269@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Asandeutertinib: Phase 2 readout est. (NCT06672068)
DESCRIPTION:Asandeutertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients Wi
 th Mutated Epidermal Growth Factor Receptor NSCLC\nEstimated primary compl
 etion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/asandeutertinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06672068
URL:https://assetmemo.bio/drug/asandeutertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
